62 results
F-1/A
EX-10.3
CNTB
Connect Biopharma Holdings Ltd
17 Mar 21
Registration statement (foreign) (amended)
6:38am
the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation with respect … to an Award (including Shares retained by the Company from the Award or Prior Plan Award being exercised or purchased and/or creating the tax obligation
F-3/A
CNTB
Connect Biopharma Holdings Ltd
20 May 22
Shelf registration (foreign) (amended)
6:54pm
are required to set aside at least 10% of its after-tax profits each year, if any, to fund specific statutory reserve funds until such reserve funds … reach 50% of its registered capital. In addition, each of our PRC subsidiaries may allocate a portion of its after-tax profits based on PRC accounting
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
, regulatory and tax-related services, associated with maintaining compliance with Nasdaq listing and SEC requirements, director and officer insurance … . Our financial instruments with preferred rights were converted into our ordinary shares upon completion of our IPO.
Income Taxes
Income tax
F-3
CNTB
Connect Biopharma Holdings Ltd
15 Apr 22
Shelf registration (foreign)
5:27pm
, and their subsidiaries are required to set aside at least 10% of its after-tax profits each year, if any, to fund specific statutory reserve funds … until such reserve funds reach 50% of its registered capital. In addition, each of our PRC subsidiaries may allocate a portion of its after-tax profits
F-1/A
EX-10.3
CNTB
Connect Biopharma Holdings Ltd
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation with respect … to an Award (including Shares retained by the Company from the Award or Prior Plan Award being exercised or purchased and/or creating the tax obligation
F-1
EX-10.14
2w4upd
26 Feb 21
Registration statement (foreign)
4:56pm
DRS
yb0gsmi6exz
17 Dec 20
Draft registration statement
12:00am
F-1/A
1cuhcrcv73a02myvch
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
6-K
yoeo4l7qckw2e
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
weeola 3m
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-1/A
kd69p huds19s
18 Mar 21
Registration statement (foreign) (amended)
6:15am
F-3/A
z8jbvnqu8
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
UPLOAD
06hwoum 8eh6ch
16 Mar 21
Letter from SEC
12:00am
F-1/A
drcaid 2sw0z4lxjtc
17 Mar 21
Registration statement (foreign) (amended)
6:38am
S-8
EX-4.3
hgv3t4nd999ll67 vbx0
19 Mar 21
Registration of securities for employees
5:13pm
F-1MEF
vv3sonvc
18 Mar 21
Registration statement to add securities to prior F-1 registration
9:02pm
F-1/A
EX-8.3
3y0rzfkpy7zkm4h1s
17 Mar 21
Registration statement (foreign) (amended)
6:38am
F-1MEF
EX-8.3
46zhff5 98bzq
18 Mar 21
Registration statement to add securities to prior F-1 registration
9:02pm
F-1
EX-10.12
v1gs33j tzf1s
26 Feb 21
Registration statement (foreign)
4:56pm
20-F
a3s n0qtb
31 Mar 22
Annual report (foreign)
4:33pm